Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.